Llwytho...
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
BACKGROUND: An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adults. OBJECTIVES: To determine the pharmacokinetic profile of extended-release amantadine...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | CNS Drugs |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer International Publishing
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6669187/ https://ncbi.nlm.nih.gov/pubmed/31342404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-019-00651-1 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|